Fresenius Medical Care AG & Co. KGaA (FME) Given Consensus Recommendation of “Buy” by Brokerages

Fresenius Medical Care AG & Co. KGaA (ETR:FME) has earned a consensus recommendation of “Buy” from the twenty ratings firms that are currently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is €82.68 ($96.14).

A number of research analysts recently issued reports on the company. Goldman Sachs Group set a €79.00 ($91.86) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Monday, April 1st. JPMorgan Chase & Co. set a €85.90 ($99.88) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Wednesday, February 27th. Berenberg Bank set a €88.65 ($103.08) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Deutsche Bank set a €100.00 ($116.28) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Tuesday. Finally, Credit Suisse Group set a €66.00 ($76.74) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Thursday, December 13th.

ETR FME opened at €74.40 ($86.51) on Friday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €55.44 ($64.47) and a 52 week high of €91.74 ($106.67). The stock has a market cap of $22.82 billion and a PE ratio of 11.53. The company has a quick ratio of 0.96, a current ratio of 1.25 and a debt-to-equity ratio of 58.49.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Story: Is it better to buy a fund with a higher or lower NAV?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.